These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 19662384

  • 1. Specific effects of escitalopram on neuroendocrine response.
    Hawken ER, Owen JA, Hudson RW, Delva NJ.
    Psychopharmacology (Berl); 2009 Nov; 207(1):27-34. PubMed ID: 19662384
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses.
    Nadeem HS, Attenburrow MJ, Cowen PJ.
    Neuropsychopharmacology; 2004 Sep; 29(9):1699-703. PubMed ID: 15127082
    [Abstract] [Full Text] [Related]

  • 3. Effects of oral racemic citalopram on neuroendocrine responses.
    Hawken ER, Owen JA, Van Vugt D, Delva NJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):694-700. PubMed ID: 16563590
    [Abstract] [Full Text] [Related]

  • 4. L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI.
    Lowe SL, Yeo KP, Teng L, Soon DK, Pan A, Wise SD, Peck RW.
    Psychoneuroendocrinology; 2006 May; 31(4):473-84. PubMed ID: 16378695
    [Abstract] [Full Text] [Related]

  • 5. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences.
    Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG.
    Psychopharmacology (Berl); 2005 Mar; 178(2-3):268-75. PubMed ID: 15365685
    [Abstract] [Full Text] [Related]

  • 6. Escitalopram prolonged fear induced by simulated public speaking and released hypothalamic-pituitary-adrenal axis activation.
    Garcia-Leal C, Del-Ben CM, Leal FM, Graeff FG, Guimarães FS.
    J Psychopharmacol; 2010 May; 24(5):683-94. PubMed ID: 19251828
    [Abstract] [Full Text] [Related]

  • 7. [Escitalopram and citalopram: the unexpected role of the R-enantiomer].
    Jacquot C, David DJ, Gardier AM, Sánchez C.
    Encephale; 2007 May; 33(2):179-87. PubMed ID: 17675913
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of stress-induced pituitary hormone release and cardiovascular activation by antidepressant treatment in healthy men.
    Jezová D, Duncko R.
    J Psychopharmacol; 2002 Sep; 16(3):235-40. PubMed ID: 12236631
    [Abstract] [Full Text] [Related]

  • 9. Effect of sleep deprivation on neuroendocrine response to a serotonergic probe in healthy male subjects.
    Seifritz E, Müller MJ, Annen O, Nil R, Hatzinger M, Hemmeter U, Moore P, Holsboer-Trachsler E.
    J Psychiatr Res; 1997 Sep; 31(5):543-54. PubMed ID: 9368196
    [Abstract] [Full Text] [Related]

  • 10. State and trait abnormalities in serotonin function in major depression.
    Bhagwagar Z, Whale R, Cowen PJ.
    Br J Psychiatry; 2002 Jan; 180():24-8. PubMed ID: 11772847
    [Abstract] [Full Text] [Related]

  • 11. Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique.
    Rausch JL, Corley KM, Hobby HM.
    J Clin Psychopharmacol; 2004 Apr; 24(2):209-13. PubMed ID: 15206668
    [Abstract] [Full Text] [Related]

  • 12. Low-dose citalopram as a 5-HT neuroendocrine probe.
    Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ.
    Psychopharmacology (Berl); 2001 May; 155(3):323-6. PubMed ID: 11432696
    [Abstract] [Full Text] [Related]

  • 13. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats.
    Mørk A, Kreilgaard M, Sánchez C.
    Neuropharmacology; 2003 Aug; 45(2):167-73. PubMed ID: 12842122
    [Abstract] [Full Text] [Related]

  • 14. The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial.
    Knorr U, Vinberg M, Gether U, Winkel P, Gluud C, Wetterslev J, Kessing LV.
    Psychiatry Res; 2012 Dec 30; 200(2-3):354-60. PubMed ID: 22703642
    [Abstract] [Full Text] [Related]

  • 15. Escitalopram: a review of its use in the management of anxiety disorders.
    Dhillon S, Scott LJ, Plosker GL.
    CNS Drugs; 2006 Dec 30; 20(9):763-90. PubMed ID: 16953656
    [Abstract] [Full Text] [Related]

  • 16. [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine].
    Owens JM, Knight DL, Nemeroff CB.
    Encephale; 2002 Dec 30; 28(4):350-5. PubMed ID: 12232544
    [Abstract] [Full Text] [Related]

  • 17. Acute hormonal changes after IV citalopram and treatment response in OCD.
    Corregiari FM, Gattaz WF, Bernik M.
    Psychopharmacology (Berl); 2007 Sep 30; 193(4):487-94. PubMed ID: 17492272
    [Abstract] [Full Text] [Related]

  • 18. Acute citalopram administration produces correlated increases in plasma and salivary cortisol.
    Bhagwagar Z, Hafizi S, Cowen PJ.
    Psychopharmacology (Berl); 2002 Aug 30; 163(1):118-20. PubMed ID: 12185409
    [Abstract] [Full Text] [Related]

  • 19. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration.
    Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, Han M, Saito R, Hashimoto K.
    Pharmacol Biochem Behav; 2016 May 30; 144():7-12. PubMed ID: 26892759
    [Abstract] [Full Text] [Related]

  • 20. Escitalopram: a unique mechanism of action.
    Bræstrup C, Sanchez C.
    Int J Psychiatry Clin Pract; 2004 May 30; 8 Suppl 1():11-3. PubMed ID: 24930683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.